Mangesh Deshmukh1,2,3, Sanjay Patole3,4. 1. Department of Neonatalogy, Fiona Stanley Hospital, Perth, Western Australia. 2. Department of Neonatalogy, St. John of God Hospital, Subiaco, Perth, Western Australia. 3. School of Medicine, University of Western Australia, Perth, Western Australia. 4. Department of Neonatal Pediatrics, King Edward Memorial Hospital, Perth, Western Australia.
Abstract
BACKGROUND: Administration of antenatal corticosteroids (ANC) for impending preterm delivery beyond 34 weeks of gestation continues to be a controversial issue despite various guidelines for obstetricians and gynaecologists. OBJECTIVE: To compare outcomes following exposure to ANC for infants born between 34-36+6 weeks' gestation. METHODS: A systematic review of randomised controlled trials (RCT) reporting neonatal outcomes after ANC exposure between 34-36+6 weeks' gestation using Cochrane methodology. Databases including PubMed, Embase, Emcare, Cochrane Central library and Google Scholar were searched in May 2020. Primary outcomes: (1) Need for respiratory support (Mechanical ventilation, CPAP, high flow) or oxygen (2) Hypoglycemia. Secondary outcomes included respiratory distress syndrome (RDS), transient tachypnoea of newborn (TTN), need for neonatal resuscitation at birth [only in the delivery room immediately after birth (not in neonatal intensive care unit (NICU)], admission to NICU, mortality and developmental follow up. Level of evidence (LOE) was summarised by GRADE guidelines. MAIN RESULTS: Seven RCTs (N = 4144) with low to high risk of bias were included. Only one RCT was from high income countries, Meta-analysis (random-effects model) showed (1) reduced need for respiratory support [5 RCTs (N = 3844); RR = 0.68 (0.47-0.98), p = 0.04; I2 = 55%; LOE: Moderate] and (2) higher risk of neonatal hypoglycaemia [4 RCTs (N = 3604); RR = 1.61(1.38-1.87), p<0.00001; I2 = 0%; LOE: High] after ANC exposure. Neonates exposed to ANC had reduced need for resuscitation at birth. The incidence of RDS, TTN and surfactant therapy did not differ significantly. None of the included studies reported long-term developmental follow up. CONCLUSIONS: Moderate quality evidence indicates that ANC exposure reduced need for respiratory support, and increased the risk of hypoglycaemia in late preterm neonates. Large definitive trials with adequate follow up for neurodevelopmental outcomes are required to assess benefits and risks of ANC in this population.
BACKGROUND: Administration of antenatal corticosteroids (ANC) for impending preterm delivery beyond 34 weeks of gestation continues to be a controversial issue despite various guidelines for obstetricians and gynaecologists. OBJECTIVE: To compare outcomes following exposure to ANC for infants born between 34-36+6 weeks' gestation. METHODS: A systematic review of randomised controlled trials (RCT) reporting neonatal outcomes after ANC exposure between 34-36+6 weeks' gestation using Cochrane methodology. Databases including PubMed, Embase, Emcare, Cochrane Central library and Google Scholar were searched in May 2020. Primary outcomes: (1) Need for respiratory support (Mechanical ventilation, CPAP, high flow) or oxygen (2) Hypoglycemia. Secondary outcomes included respiratory distress syndrome (RDS), transient tachypnoea of newborn (TTN), need for neonatal resuscitation at birth [only in the delivery room immediately after birth (not in neonatal intensive care unit (NICU)], admission to NICU, mortality and developmental follow up. Level of evidence (LOE) was summarised by GRADE guidelines. MAIN RESULTS: Seven RCTs (N = 4144) with low to high risk of bias were included. Only one RCT was from high income countries, Meta-analysis (random-effects model) showed (1) reduced need for respiratory support [5 RCTs (N = 3844); RR = 0.68 (0.47-0.98), p = 0.04; I2 = 55%; LOE: Moderate] and (2) higher risk of neonatal hypoglycaemia [4 RCTs (N = 3604); RR = 1.61(1.38-1.87), p<0.00001; I2 = 0%; LOE: High] after ANC exposure. Neonates exposed to ANC had reduced need for resuscitation at birth. The incidence of RDS, TTN and surfactant therapy did not differ significantly. None of the included studies reported long-term developmental follow up. CONCLUSIONS: Moderate quality evidence indicates that ANC exposure reduced need for respiratory support, and increased the risk of hypoglycaemia in late preterm neonates. Large definitive trials with adequate follow up for neurodevelopmental outcomes are required to assess benefits and risks of ANC in this population.
Authors: Alessandro Liberati; Douglas G Altman; Jennifer Tetzlaff; Cynthia Mulrow; Peter C Gøtzsche; John P A Ioannidis; Mike Clarke; P J Devereaux; Jos Kleijnen; David Moher Journal: Ann Intern Med Date: 2009-07-20 Impact factor: 25.391
Authors: Iwa Antonow-Schlorke; Alexandra Helgert; Christine Gey; Turhan Coksaygan; Harald Schubert; Peter W Nathanielsz; Otto W Witte; Matthias Schwab Journal: Obstet Gynecol Date: 2009-01 Impact factor: 7.661
Authors: Elaine M Boyle; Samantha Johnson; Bradley Manktelow; Sarah E Seaton; Elizabeth S Draper; Lucy K Smith; Jon Dorling; Neil Marlow; Stavros Petrou; David J Field Journal: Arch Dis Child Fetal Neonatal Ed Date: 2015-04-01 Impact factor: 5.747
Authors: Mark A Clapp; Alexander Melamed; Taylor S Freret; Kaitlyn E James; Cynthia Gyamfi-Bannerman; Anjali J Kaimal Journal: JAMA Netw Open Date: 2022-05-02
Authors: Noorazizah Arsad; Nurlina Abd Razak; Mohd Hashim Omar; Mohamad Nasir Shafiee; Aida Kalok; Fook Choe Cheah; Pei Shan Lim Journal: Int J Environ Res Public Health Date: 2022-04-25 Impact factor: 4.614